Synthesis of amino-acid derivatives of formononetin and cladrin

Synthesis and crystal structure of 5-(8-(((2-carboxyethyl)ammonio)methyl)-7-hydroxy-4-oxo-4H-chromen-3-yl)-2-hydroxybenzenesulfonate trihydrate, C19H23NO12S

C19H23NO12S, triclinic, P1̄ (no. 2), a = 8.3926(9) Å, b = 9.0469(6) Å, c = 15.3442(15) Å, α = 78.195(7)°, β = 74.352(9)°, γ = 70.169(8)°, V = 1047.08(18) Å3, Z = 2, R gt(F) = 0.0538, wR ref(F2 ) = 0.1289, T = 293(2) K.

Synthesis and crystal structure of trans-tetraaqua-bis(3-(((7-hydroxy-3-(4-hydroxy-3-sulfonatophenyl)-4-oxo-4H-chromen-8-yl)methyl)ammonio)propanoato-κO)zinc(II) tetrahydrate, C38H48N2O26S2Zn

C38H48N2O26S2Zn, monoclinic, P21/c (no. 14), a = 15.7219(7) Å, b = 8.0394(4) Å, c = 17.1968(8) Å, β = 92.210(4)°, V = 2171.97(18) Å3, Z = 2, Rgt(F) = 0.0395, wRref(F2) = 0.0951, T = 293(2) K.

Discovery and synthesis of novel magnolol derivatives with potent anticancer activity in non-small cell lung cancer

EGFR T790 M accounts for 50% to 60% of cases of non-small-cell lung carcinoma (NSCLC) resistance to the first-generation EGFR tyrosine kinase inhibitors (TKIs). Hence, identifying novel compounds with activity against TKIs resistant is of great value. In this study, twenty honokiol and magnolol derivatives were isolated from the EtOH extract of Magnolia officinalis and the antiproliferative activity was evaluated on HCC827 (19del EGFR mutation), H1975 (L858 R/T790 M EGFR mutation), and H460 (KRAS mutation) cell lines. Among the isolated compounds, piperitylmagnolol (a 3-substituted magnolol derivative) showed the best antiproliferative activity against those three cell lines with the IC₅₀ values of 15.85, 15.60 and 18.60 μM, respectively, which provided a direction for the structural modification of magnolol. Further structural modification led to the synthesis of thirty-one magnolol derivatives, and compounds A13, C1, and C2 exhibited significant and broad-spectrum antiproliferative activity with the IC₅₀ values ranging from 4.81 to 13.54 μM, which were approximately 4- and 8-fold more potent than those of honokiol and magnolol, respectively. Moreover, their aqueous solubility was remarkably improved with 12-, 400- and 10⁵ fold greater than those of honokiol and magnolol. Anti-tumor mechanism research revealed that these three compounds were able to induce cell cycle arrest at G0/G1 phase, cause efficient apoptosis in H1975 cells, and also prevent the migration of HUVECs in a dose-dependent manner through Cdk2, Cdk4, Cyclin E, and Cyclin D1 inhibition as well as up-regulation of cleaved-PARP and cleaved-caspase 3 levels. In in vivo antitumor activity, C2 (10, 30 and 100 mg/kg, po) dose-dependently inhibited the tumor growth in H1975 xenograft model with the tumor inhibition rate of 46.3%, 59.3% and 61.2% respectively, suggesting that C2 is a potential oral anticancer agent deserving further investigation.

Synthesis and crystal structure poly[aqua(μ3-2-(((7-hydroxy-3-(4-hydroxy-3-sulfonatophenyl)-4-oxo-4H-chromen-8-yl)methyl)ammonio)acetate-κ4 O,O′:O′′:O′′′) sodium] monohydrate, C18H18NNaO11S

C18H18NNaO11S, triclinic, P1̅ (no. 2), a = 8.2627(12) Å, b = 8.6490(11) Å, c = 14.1791(17) Å, α = 82.883(10)°, β = 76.954(12)°, γ = 69.729(12)°, V = 924.8(2) Å3, Z = 2, R gt(F) = 0.0574, wR ref(F 2) = 0.1609, T = 293(2) K.

Synthesis and crystal structure of trans-tetraqua-bis(2-(((7-hydroxy-3-(4-hydroxy-3-sulfonatophenyl)-4-oxo-4H-chromen-8-yl)methyl)ammonio)acetato-κO)cobalt(II) hexahydrate, C36H48CoN2O28S2

C36H48CoN2O28S2, monoclinic, P21/c (no. 14), a = 18.2239(13) Å, b = 7.1282(6) Å, c = 17.8550(13) Å, β = 97.883(2)°, V = 2297.5(3) Å3, Z = 2, Rgt(F) = 0.0906, wRref(F2) = 0.1998, T = 293(2) K.

Development of 6H-Chromeno[3,4-c]pyrido[3',2':4,5]thieno[2,3-e]pyridazin-6-ones as Par-4 Secretagogues

Nitrosation and cyclization of 4-(3-aminothieno[2,3-b]pyridine-2-yl)-2H-chromen-2-ones 1 afforded substituted 6H-chromeno[3,4-c]pyrido[3',2':4,5]thieno[2,3-e]pyridazin-6-ones 2 that inhibited the intermediary filament protein, vimentin, at low micromolar concentrations. This inhibition promoted the secretion of Prostate Apoptosis Response-4 protein (Par-4), which selectively triggered apoptosis in prostate cancer cells such as CWR22Rv1, LNCaP-derivative C4-2B, PC-3 and its aggressive analog, PC-3 MM2.